相关实验视频

Updated: May 9, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

免疫检查点抑制剂治疗作为肌肉侵入性膀癌的新辅助治疗:叙述性综述

Sentai Ding^1,2, Chenrui Wu^1,2, Jishuang Cao^1,2

¹Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Current urology

|May 2, 2025

概括

新辅助免疫疗法对肌肉侵入性膀癌具有前途. 需要进一步的大规模试验来确认长期益处,并确定免疫检查点抑制剂治疗的响应者.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
泌尿器科泌尿器科泌尿器科泌尿器科

背景情况:

免疫疗法是晚期泌尿腺癌的标准治疗方法.
新辅助免疫疗法越来越多地被用于早期膀癌.

研究的目的:

审查免疫检查点抑制剂 (ICI) 在肌肉侵入性膀癌 (MIBC) 的新辅助治疗中的初步发现和临床见解.
突出有效性,并确定MIBC新辅助疗法的未来研究领域.

主要方法:

对现有文献进行审查,重点关注临床研究.
对小样本,单臂II期试验的分析.
强调病理完整反应率作为主要终点.

主要成果:

早期的结果表明,ICI在膀癌的新辅助治疗中具有有希望的疗效.
病理完整反应率是当前研究中的一个关键指标.
在这些研究中,正在考虑不同的患者群体.

结论:

新辅助剂ICI在治疗MIBC方面显示出潜力.
在大规模的III期试验中确认是必不可少的.
进一步的研究应侧重于长期生存和患者选择以获得最佳反应.

关键词:

免疫检查点抑制剂免疫检查点抑制剂肌肉侵入性膀癌是一种肌肉侵入性膀癌.新辅助免疫疗法新辅助免疫疗法这就是Tislelizumab.

更多相关视频

Mouse Bladder Wall Injection

Mouse Bladder Wall Injection

Published on: July 12, 2011

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.